Robert Klein Email & Phone Number

Stealth gene therapy company.

San Carlos, California, US

Providing consultancy services specializing in business development, scientific strategy, partnership/collaborations, and go-to-market strategy in the genomics, population genomics, genomics tools, very high performance compute, diagnostics, and therapeutics space.

San Jose, CA, US

• Responsible for commercial operations including bringing to market Complete Genomics’ (CG) large-scale sequencing solution competing with Illumina’s X Ten system. Also responsible for technology licensing, corporate.
• Demonstrated value of whole-genome sequencing (WGS) by setting up and executing ~20 clinical utility studies comparing WGS to clinical standard of care. Results overwhelmingly showed improved diagnostic yield on CG.
• Closed purchase agreements for multiple systems with high profile clinical institutions.
• First year new product sales of $65M to clinical / hospital groups.
• Built robust deal pipeline (~$200M near term) and clear path to company profitability.

Omaha, NE, US

• iKaryos Diagnostic used whole-genome information to provide better diagnostic, prognostic, and therapeutic management decisions for cancer patients. iKaryos was built using technology licensed from a University and.
• Raised seed capital for initial operations. This capital, along with product revenue, was sufficient to run the company through its sale in 2011.
• Negotiated and executed international distribution agreements in Asia, the Middle East, and Australia.

Burlingame, California, US

• Amnestix developed therapeutics for Alzheimer’s and related diseases. The initial technology was licensed from TGEN (Pheonix, AZ) from discoveries linking genetic variations with memory recall. High memory performers.
• Managed all scientific interactions with TGEN.
• Initiated pre-clinical IND enabling studies for repurposed compounds.
• Part of three person transaction team that sold the company to Sygnis Pharma AG.

New York, New York, US

• Rinat Neuroscience develops protein therapeutics for neuroscience indications including Alzheimer’s disease, pain, migraine, and other areas. Had a duel role in research and BD. On the research side, had a team of 8.
• Executed an all cash acquisition of Rinat by Pfizer as a member of six person transaction team. Was the largest cash transaction for a private biotech at the time.
• Identified, negotiated, and executed two in-licensing deals for potential therapeutic proteins. One of these is now in pre-clinical development.
• Directed Rinat’s research efforts in migraine, Alzheimer’s disease, Parkinson’s disease, nociceptive pain, neuropathic pain, and other early discovery areas. Alzheimer’s drug (RN1219) is in clinical trials and migraine.

US

• Rinat Neuroscience develops protein therapeutics for neuroscience indications including Alzheimer’s disease, pain, migraine, and other areas. Had a duel role in research and BD. On the research side, had a team of 8.
• Executed an all cash acquisition of Rinat by Pfizer as a member of six person transaction team. Was the largest cash transaction for a private biotech at the time.
• Identified, negotiated, and executed two in-licensing deals for potential therapeutic proteins. One of these is now in pre-clinical development.
• Directed Rinat’s research efforts in migraine, Alzheimer’s disease, Parkinson’s disease, nociceptive pain, neuropathic pain, and other early discovery areas. Alzheimer’s drug (RN1219) is in clinical trials and migraine.

US

• Deltagen created genetically modified mice to accurately predict targets for human drug development. On the technology side, I was the first employee and set up all laboratory operations, created operational procedures.
• Initiated and negotiated exclusive licenses for Deltagen’s validated targets in rheumatoid arthritis, inflammatory bowel disease, anxiety, and diabetes/metabolic disease.Invented essentially all the technology for.

South San Francisco, California, US

• Post doc and scientist in the Neuroscience department. Also was an RA at Genentech prior to grad school.
• Identified, cloned and biochemically characterized neurturin binding receptor (GFRa2) and demonstrated that RET acts as the signaling component.
• Project team leader for Genentech’s lead protein therapeutic for treatment of Parkinson’s Disease (neurturin) leading to development decision.
• Invented technology that started Genentech’s genomics efforts (signal sequence trap for cloning of secreted proteins). Resulted in Genentech’s largest single research effort to date.

A.B., Biochemistry

Ph.D., Biology